Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 19/20 | 0.46 |
| ▸ | PPARA | Q07869 | 6/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14449269 | 0.91 | PPARD (0.37) | PPARDPPARAPPARGPTGDR2MEN1 | |
| SCHEMBL4654024 | 0.90 | PPARD (0.47) | PPARDPPARAPPARGPTGDR2 | |
| SCHEMBL14016284 | 0.87 | PPARD (0.33) | PPARDPPARAPPARGPTGDR2 | |
| SCHEMBL4655286 | 0.85 | PPARD (0.55) | PPARDPPARAPPARG | |
| SCHEMBL4654136 | 0.83 | PPARD (0.47) | PPARDPPARAPPARGPTGDR2 | |
| SCHEMBL5157725 | 0.83 | PPARD (0.47) | PPARDPPARAPPARG | |
| SCHEMBL4654025 | 0.83 | PPARD (0.52) | PPARDPPARAPPARG | |
| SCHEMBL14449268 | 0.82 | PPARD (0.41) | PPARDPPARAPPARGPTGDR2 | |
| SCHEMBL4654150 | 0.82 | PTGDR2 (0.46) | PPARDPPARAPPARGPTGDR2 | |
| SCHEMBL4654065 | 0.81 | PTGDR2 (0.45) | PPARDPPARAPPARGPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740568-B1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE. | SMITHKLINE BEECHAM CORP (US) | 2008-11-26 | — | — | EP | claimed |
| JP-2007522178-A | — | — | 2007-08-09 | — | — | JP | claimed |
| US-20070155805-A1 | Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | claimed |
| EP-1740568-A2 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE. | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-10 | — | — | EP | claimed |
| WO-2005077926-A2 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | claimed |
| EP-1740568-B1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE. | SMITHKLINE BEECHAM CORP (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20070155805-A1 | Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| US-20070155805-A1 | Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| US-20070155805-A1 | Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| EP-1740568-A2 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE. | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005077926-A2 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155805-A1 | Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease | ABAT, BPTF, TNNT2 | PPARD 47/4885PPARA 115/4885PPARG 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.